1. Search Result
Search Result
Results for "

IG

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

18

Inhibitory Antibodies

1

Natural
Products

93

Recombinant Proteins

15

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99933

    IMP321; LAG-3IG

    LAG-3 Cancer
    Eftilagimod alfa (IMP321) is a recombinant LAG-3Ig fusion protein that binds to MHC class II. Eftilagimod alfa mediates antigen-presenting cell (APC) activation followed by CD8 T-cell activation. Eftilagimod alfa can be used for metastatic melanoma and metastatic breast carcinoma research .
    Eftilagimod alfa
  • HY-147311

    PD-1/PD-L1 Inflammation/Immunology
    NSC622608 is a V-domain Ig suppressor of T-cell activation (VISTA) ligand with an IC50 value of 4.8 μM .
    NSC622608
  • HY-122663

    TNF Receptor Cancer
    (Rac)-BIO8898 is a CD40-CD154 co-stimulatory interaction inhibitor. (Rac)-BIO8898 inhibits CD154 binding to CD40-Ig with an IC50 of 25 μM .
    (Rac)-BIO8898
  • HY-P99963

    HS636

    PD-1/PD-L1 Cancer
    Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .
    Sudubrilimab
  • HY-P99577

    CD19 Cancer
    Taplitumomab paptox is an anti-CD19 monoclonal antibody. Taplitumomab paptox can be used in cancer research.
    Taplitumomab paptox
  • HY-122663A

    TNF Receptor Apoptosis Metabolic Disease
    BIO8898 is a potent CD40-CD154 inhibitor. BIO8898 inhibits soluble CD40L binding to CD40-Ig with an IC50 value of 25 µM. BIO8898 inhibits CD40L-induced apoptosis .
    BIO8898
  • HY-P99868

    MGD 011

    CD19 Others
    Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E .
    Duvortuxizumab
  • HY-P99883

    SAR156597

    Interleukin Related Others
    Romilkimab (SAR156597) is a chimeric humanized IG antibody that specifically targets IL-4 and IL13 .
    Romilkimab
  • HY-N6008

    Others Others
    7-O-Methyl morroniside is an iridoid glycoside (IG) extracted from Cornus officinalis fructus, used in many traditional Chinese medicines .
    7-O-Methyl morroniside
  • HY-P99040

    JNJ-61610588

    PD-1/PD-L1 Cancer
    Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab has an anti-tumor activity .
    Onvatilimab
  • HY-103358

    P-selectin Inflammation/Immunology
    KF38789 is a selective inhibitor of P-selectin-PSGL-1 binding. KF38789 inhibits the binding of U937 cells to immobilized P-selectin immunoglobulin G chimeric protein (P-selectin-Ig) with an IC50 value of 1.97 μM .
    KF38789
  • HY-NP006

    SPA

    Endogenous Metabolite Inflammation/Immunology
    Protein A (SPA) is an immunoglobulin (Ig) binding protein that exists on the surface of bacteria and can be freely secreted into the extracellular environment. Protein A blocks opsonization and phagocytosis and induces B-cell death in vitro by binding to the Fc region of antibodies and the Fab region of B-cell receptors. Protein A has the ability to inhibit opsonization and phagocytosis in vitro .
    Protein A
  • HY-124066

    TAM Receptor Cancer
    RU-302 is a pan TAM inhibitor that blocks the interface between the TAM Ig1 ectodomain and the Gas6 Lg domain. RU-302 effectively blocks Gas6-inducible Axl receptor activation with a low micromolar IC50in cell assays, and suppresses lung cancer tumor growth .
    RU-302
  • HY-108801

    VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1

    VEGFR Cardiovascular Disease Metabolic Disease
    Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
    Aflibercept
  • HY-P99371

    AK002; Anti-SIGlec-8 Reference Antibody (lirentelimab)

    Apoptosis Inflammation/Immunology
    Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
    Lirentelimab
  • HY-108801A

    VEGFR Cardiovascular Disease Metabolic Disease
    Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
    Aflibercept (VEGF Trap)
  • HY-101813

    HR325

    Dihydroorotate Dehydrogenase DNA/RNA Synthesis Prostaglandin Receptor Inflammation/Immunology
    Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH). Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 µM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor .
    Laflunimus
  • HY-P99386

    MNRP-1685A

    Complement System Cancer
    Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer .
    Vesencumab
  • HY-155971

    Autophagy Inflammation/Immunology Cancer
    VISTA-IN-2 (Compound 1) is an inhibitor of V-domain Ig suppressor of T-cell activation (VISTA). VISTA-IN-2 induces VISTA degradation in cells through an autophagic mechanism. VISTA-IN-2 rescues VISTA-mediated immunosuppression, and enhances antitumor activity of immune cells. VISTA-IN-2 also activates the antitumor immunity and inhibits tumor growth in a CT26 mouse model .
    VISTA-IN-2
  • HY-P99692

    p55TNF-R:IG; Ro 45-2081; TNFR55-IGG1

    TNF Receptor Inflammation/Immunology
    Lenercept (Ro 45-2081) is a recombinant fusion protein that consists of the soluble TNF-receptor (p55) linked to the Fc portion of human IgG1 .
    Lenercept

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: